<DOC>
	<DOCNO>NCT00878722</DOCNO>
	<brief_summary>An open-label , non-randomized , multi-centre , Phase I/II trial ass efficacy safety 2 schedule PXD101 combination idarubicin patient AML suitable standard intensive therapy .</brief_summary>
	<brief_title>Trial PXD101 ( Belinostat ) Combination With Idarubicin Treat AML Not Suitable Standard Intensive Therapy</brief_title>
	<detailed_description>This trial open-label , multi-centre , dose-escalation Phase I/II study evaluate safety , explore efficacy , pharmacodynamics , pharmacokinetics combination PXD101 idarubicin administer two different schedule patient AML . The PXD101 plus idarubicin treatment repeat suitable interval ( target every 3 week schedule A every 2 week schedule B ) depend upon toxicity disease progression . Safety efficacy assessment perform every cycle . Schedule A us PXD101 30 min infusion daily 5 day every 3 week escalate dos idarubicin . Schedule B use escalate dos continuous infusion ( 48h ) PXD101 alone combination idarubicin . In regimens trial may expand Maximum Tolerated Dose ( MTD ) .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>( abbreviate ) 1 . Signed consent 2 . AML patient : 1. 60 year first relapse refractory . 2 . 1860 year 2nd relapse refractory least two intensive chemotherapy regimen . 3. 60 year high risk feature ( cytogenetics , secondary treatment related AML ) ) 60 year myelodysplastic syndrome &gt; 10 % blast bone marrow ( WHO RAEB2 ( Refractory anemia excess blasts2 ) ) . For patient 60 year potential curative treatment exhaust . 3 . Performance status ( ECOG ) ≤ 2 4 . Age ≥ 18 year 5 . Acceptable liver , renal bone marrow function define 6 . Serum potassium within normal range . 7 . Acceptable coagulation status define 8 . Precautions female patient reproductive potential define 1 . Treatment investigational agent within last 4 week 2 . Prior treatment HDAC ( Histone deacetylases ) inhibitor include valproic acid 3 . Prior antileukemic therapy ( except hydroxyurea ) within last 3 week trial dose 4 . Coexisting active infection ( include HIV ) coexist medical condition likely interfere trial procedure , include significant cardiovascular disease 5 . Altered mental status preclude understand informed consent process and/or completion necessary study procedure . 6 . Concurrent second malignancy . 7 . History hypersensitivity idarubicin 8 . Cumulative idarubicin dose exceed 100 mg/m² , ( respect cardiotoxicity ) correspond dose anthracyclines 9 . LVEF ( leave ventricular ejection fraction ) normal range ( &lt; 45 % ) 10 . Known Central Nervous System ( CNS ) leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>PXD101</keyword>
	<keyword>Belinostat</keyword>
	<keyword>Idarubicin</keyword>
</DOC>